Swiss National Bank boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 36.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 486,700 shares of the company's stock after purchasing an additional 129,600 shares during the period. Swiss National Bank owned approximately 0.12% of Recursion Pharmaceuticals worth $3,290,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $27,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after purchasing an additional 6,758 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.25.
View Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Down 2.7 %
Recursion Pharmaceuticals stock traded down $0.16 during trading hours on Friday, hitting $5.81. The company had a trading volume of 15,132,783 shares, compared to its average volume of 10,753,135. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market cap of $2.34 billion, a P/E ratio of -3.80 and a beta of 0.85. The company has a 50-day moving average price of $7.44 and a two-hundred day moving average price of $7.01. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) EPS. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Recursion Pharmaceuticals Profile
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
